---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-011473"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:25:00.792774+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Xilio Q2 net loss $15.8M, cash $121.6M; pipeline progress on vilastobart and masked T cell engagers

## Summary
- Net loss $15.8M in Q2 2025 vs $13.9M a year ago; cash and equivalents $121.6M vs $55.3M at Dec 31, 2024.
- Vilastobart Phase 2 data at ASCO: 26% objective response rate in heavily pre-treated MSS CRC patients without liver metastases.
- On track to nominate first development candidates for masked T cell engagers (PSMA, CLDN18.2, STEAP1) in H2 2025.
- June 2025 follow-on offering raised ~$50M gross; up to $100M additional from warrants if exercised at $0.75 per share.
- Cash runway expected through end of Q3 2026 based on current plans.

## SEC filing metadata
- accession: 0001558370-25-011473
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837025011473/0001558370-25-011473-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837025011473/xlo-20250814x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-011473
- JSON: https://secwatch.observer/filing/0001558370-25-011473.json
- Plain text: https://secwatch.observer/filing/0001558370-25-011473.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.